CRBU · NASDAQ · Biotechnology

Caribou Biosciences (CRBU)

Develops genome-edited allogeneic CAR-T candidates for blood cancers.

$1.34
After hours−0.01 (−0.74%)
At close$1.35(+3.85%)

Something off on this page? Send us feedback.

Next report
Nov 11, 26
estimated · in 50 days
EPS estimate
−$0.29
Revenue estimate
$2.2M
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.39−$0.43−$0.35−$0.30−$0.28−$0.26−$0.24Pending
Estimate−$0.40−$0.43−$0.40−$0.36−$0.33−$0.33−$0.32−$0.29
Surprise+2.5%0.0%+12.5%+16.7%+15.2%+21.2%+25.9%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$2.1M$2.4M$2.7M$2.2M$3.9M$2.4M$1.5MPending
Estimate$2.1M$1.9M$1.5M$2.0M$2.2M$2.2M$2.3M$2.2M
Surprise−1.4%+27.1%+74.1%+12.3%+78.6%+8.3%−34.2%

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Dec 2026−$0.20
Nov 2026−$0.29
Aug 2026−$0.32−$0.24+25.9%
May 2026−$0.33−$0.26+21.2%
Mar 2026−$0.33−$0.28+15.2%
Nov 2025−$0.36−$0.30+16.7%
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Sep 2021
Jul 2021
Dec 2020
Sep 2020
Jun 2020
Mar 2020

The latest year is open to everyone — the 22 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2026−$0.20$19.2M
Nov 11, 2026−$0.29$2.2M
Aug 13, 2026−$0.32−$0.24+25.9%$2.3M$1.5M−34.2%−1.9%
May 7, 2026−$0.33−$0.26+21.2%$2.2M$2.4M+8.3%−3.6%
Mar 5, 2026−$0.33−$0.28+15.2%$2.2M$3.9M+78.6%−5.0%
Nov 12, 2025−$0.36−$0.30+16.7%$2.0M$2.2M+12.3%+0.9%
Aug 12, 2025
May 8, 2025
Mar 10, 2025
Nov 6, 2024
Aug 6, 2024
May 7, 2024
Mar 11, 2024
Nov 7, 2023
Aug 8, 2023
May 9, 2023
Mar 9, 2023
Nov 8, 2022
Aug 9, 2022
May 9, 2022
Mar 21, 2022
Nov 9, 2021
Sep 2, 2021
Jul 23, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020

The latest year is open to everyone — the 22 quarters behind it read with an account.